Tuesday , December 12 2017
Home / KEEP BUT DO NOT DISPLAY / Alerts / Germany & France suspend the use of Actos, Label Change for Zocor

Germany & France suspend the use of Actos, Label Change for Zocor

 

Germany & France suspend the use of Actos, a TZD diabetes drug, due to worries about a possible link to bladder cancer. Interim results from trials in the U.S. one of which began in 2003 and is slated to last 10 years, have so far not confirmed a clear association between Actos and bladder cancer. See More Signs Diabetes Drug Linked to Bladder Cancer for more background.

Zocor (simvastatin): Label Change: New Restrictions, contraindications, and dose limitations applied to Simvastatin sold under the brand-name Zocor, as a single-ingredient generic product, and sold in combination with ezetimibe as Vytorin and in combination with niacin as Simcor. FDA notified healthcare professionals that it is recommending limiting the use of the highest approved dose of the cholesterol-lowering medication simvastatin (80 mg) because of increased risk of muscle damage.